Inozyme Pharma, Inc. (INZY)

Jul 1, 2025 - INZY was delisted (reason: acquired by BMRN)

4.000

0.00 (0.00%)

Inactive · Last trade price on Jun 30, 2025

Inozyme Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	260	178	263	42	161	482
Market Cap Growth	-	-32.37%	520.31%	-73.72%	-66.55%	-
Enterprise Value	222	93	105	-92	40	323
Last Close Price	4.00	2.77	4.26	1.05	6.82	20.64

Price Ratios

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
PB Ratio	8.17	3.08	1.87	0.36	1.48	3.05
P/TBV Ratio	8.17	3.08	1.87	0.36	1.48	3.05

Financial Efficiency

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Debt / Equity Ratio	1.48	0.81	0.33	0.06	0.03	-
Quick Ratio	1.98	3.35	12.87	8.70	9.62	14.83
Current Ratio	2.19	3.56	13.36	8.93	9.91	15.14
Return on Equity (ROE)	-141.69%	-102.90%	-54.98%	-58.91%	-42.36%	-55.64%
Return on Assets (ROA)	-48.45%	-40.13%	-27.81%	-32.67%	-24.17%	-32.81%
Return on Invested Capital (ROIC)	-53.98%	-44.57%	-30.28%	-36.10%	-26.15%	-35.16%

Yields

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Earnings Yield	-41.10%	-57.33%	-27.05%	-158.11%	-35.08%	-11.70%
FCF Yield	-37.18%	-51.68%	-26.98%	-137.15%	-30.08%	-7.58%
Buyback Yield / Dilution	-12.57%	-21.17%	-37.27%	-60.30%	-113.46%	-832.81%

SEC Filings: 10-K · 10-Q